DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Pa-824 is an investigational drug.
There have been 21 clinical trials for Pa-824. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and Tuberculosis, Multidrug-Resistant. The leading clinical trial sponsors are Global Alliance for TB Drug Development, London School of Hygiene and Tropical Medicine, and Medecins Sans Frontieres, Netherlands.
There are fourteen US patents protecting this investigational drug and eighty-nine international patents.
Recent Clinical Trials for Pa-824
|PRACTECAL-PKPD Sub Study||Clinical HIV Reserach Unit, Wits Health Consortium||Phase 2/Phase 3|
|PRACTECAL-PKPD Sub Study||Drugs for Neglected Diseases||Phase 2/Phase 3|
|PRACTECAL-PKPD Sub Study||eResearch Technology, Inc.||Phase 2/Phase 3|
Top disease conditions for Pa-824
Top clinical trial sponsors for Pa-824
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pa-824||Start Trial||Multi-drug therapies for tuberculosis treatment||The Regents of the University of California (Oakland, CA)||Start Trial|
|Pa-824||Start Trial||Process for preparing imidazopyran derivatives||Daiso Co., Ltd. (Osaka, JP)||Start Trial|
|Pa-824||Start Trial||Method of treating latent tuberculosis||Evanston Northwestern Healthcare (Evanston, IL)||Start Trial|
|Pa-824||Start Trial||Nitroimidazooxazine and nitroimidazooxazole analogues and their uses||Global Alliance for TB Drug Development (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pa-824||European Patent Office||3215225||2034-11-03||Start Trial|
|Pa-824||World Intellectual Property Organization (WIPO)||2016073524||2034-11-03||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|